Combining therapies to treat bile duct cancer
Mechanism-based combination therapy for cholangiocarcinoma
This study is exploring new ways to treat cholangiocarcinoma, a tough bile duct cancer, by testing different combinations of drugs to see if they can work better than standard chemotherapy and help patients get longer-lasting results.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Alabama at Birmingham NIH-funded |
| Lab location | 1 site (Birmingham, United States) |
| Project ID | NIH-10821442 on NIH RePORTER |
What this research studies
This research investigates new treatment combinations for cholangiocarcinoma, an aggressive bile duct cancer that often leads to poor outcomes. The team is developing patient-derived models to test how different drug combinations can overcome resistance to standard chemotherapy. By focusing on the molecular mechanisms of drug resistance, they aim to identify effective regimens that can provide longer-lasting responses in patients. The approach includes using inhibitors alongside traditional chemotherapy to enhance treatment efficacy.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with advanced cholangiocarcinoma who have not responded well to standard chemotherapy.
Not a fit: Patients with early-stage cholangiocarcinoma or those who have not yet undergone chemotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options that improve survival rates for patients with cholangiocarcinoma.
How similar studies have performed: Other research has shown promise in using combination therapies to overcome drug resistance in various cancers, suggesting potential success for this approach in cholangiocarcinoma.
Where this research is happening
Birmingham, United States
- University of Alabama at Birmingham — Birmingham, United States (Active)
Researchers
- Principal investigator: Yoon, Karina J — University of Alabama at Birmingham
- Study coordinator: Yoon, Karina J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.